Eric RPh - Mineralys Therapeutics Chief Officer
| MLYS Stock | | | 28.06 0.12 0.43% |
Executive
Eric RPh is Chief Officer of Mineralys Therapeutics Common
| Age | 54 |
| Address | 150 N. Radnor Chester Rd., Radnor, PA, United States, 19087 |
| Phone | 888 378 6240 |
| Web | https://mineralystx.com |
Mineralys Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.2651) % which means that it has lost $0.2651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(0.4214) %, meaning that it created substantial loss on money invested by shareholders. Mineralys Therapeutics' management efficiency ratios could be used to measure how well Mineralys Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.82 in 2026.
Return On Capital Employed is likely to drop to -1.21 in 2026.
Non Current Assets Total is likely to gain to about 1
M in 2026, whereas
Total Assets are likely to drop slightly above 128.6
M in 2026.
Mineralys Therapeutics Common (MLYS) is traded on NASDAQ Exchange in USA and employs 51 people. Mineralys Therapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Mineralys Therapeutics Leadership Team
Elected by the shareholders, the Mineralys Therapeutics' board of directors comprises two types of representatives: Mineralys Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mineralys. The board's role is to monitor Mineralys Therapeutics' management team and ensure that shareholders' interests are well served. Mineralys Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mineralys Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD Tortorici, Senior Medicine | |
| Sarah Foster, Vice Resources | |
| Tiffany Burt, Senior Affairs | |
| Danielle Bradbury, Senior Assurance | |
| Jon Congleton, CEO President | |
| Minji MBA, Chief Officer | |
| Jessica Ibbitson, Executive Operations | |
| Jose CPA, Senior Controller | |
| Danielle Mahoney, Senior Assurance | |
| MD MPH, Founder Chairman | |
| Robert McKean, Senior CMC | |
| Adam Levy, CFO Secretary | |
| Eric RPh, Chief Officer | |
| Cindy Berejikian, Executive Operations | |
| Jeffrey Fellows, Senior Affairs | |
| David MD, Chief Officer | |
Mineralys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mineralys Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics' price analysis, check to
measure Mineralys Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics is operating at the current time. Most of Mineralys Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Mineralys Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics' price. Additionally, you may evaluate how the addition of Mineralys Therapeutics to your portfolios can decrease your overall portfolio volatility.